Trials Studying the Safety and Immune Response of Chronic Lymphocytic Leukemia (CLL) Patients Receiving the COVID-19 Vaccines
NCCN or National Comprehensive Cancer Network publishes well respected cancer management guidelines for physicians and patients. CLL Society is an official endorser of its CLL patient guidelines and has contributed to its content over the years.
NCCN recently posted their Preliminary Recommendations of the NCCN COVID-19 Vaccination Advisory Committee.
They start by echoing CLL Society statements advocacy campaign to get CLL patients vaccinated earlier in the roll out.
“Patients with cancer should be prioritized for vaccination (CDC priority group 1b/c) and should be immunized when vaccination is available to them”.
They also state:
“Immunization is recommended for all patients receiving active therapy, with the understanding that there are limited safety and efficacy data in these patients”.
This differs slightly from ERIC’s and our own official statement on SARS-CoV-2 vaccinations.
And finally, they remind us:
“Even if vaccinated, close contacts should continue to wear masks, maintain social distancing guidelines, and follow other recommendations for COVID-19 prevention”.
We heartily agree.
All guidelines are works in progress. Data are changing fast. You will find the latest news and recommendations.
Here are the Preliminary Recommendations of the NCCN COVID-19 Vaccination Advisory Committee.
Stay strong, we are all in this together.
Brian Koffman
Related posts